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Background: Inherited peripheral neuropathies (IPN) are the most common inherited neurological condition.
It represents a highly heterogeneous group, both clinically and genetically.
Targeted disease specific gene panel massively parallel sequencing (MPS) seems to be a useful tool in diagnosis
of disorders with high genetic heterogeneity.
Methods: In our study, we have designed, validated and updated our own custom gene panel of all known
genes associated with IPN. One hundred and ninety-eight patients have been tested so far. Only patients in whom
mutations in more common causes or relevant genes have already been excluded were enrolled. Five consecutive
panel designs were prepared according to recent literature search, the last one covering ninety-three genes. Each
patient was tested only once. All data were evaluated with at least two different pipelines.
Results: In summary, causative mutation has been found in fifty-one patients (26 %). The results were inconclusive
in thirty-one (16 %) patients. No variants of likely significance to IPN were found in one hundred and sixteen (58 %)
patients.
Conclusion: MPS gene panel enables testing of all known IPN causes at once with high coverage and at an
affordable cost making it truly a method of choice also in IPN. Gene panel testing results in several interesting
results and findings.
Keywords: Inherited peripheral neuropathies, Charcot-Marie-Tooth, Targeted gene panel testing, Mutation,
Phenotype
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Inherited peripheral neuropathies (IPN) are the most
common inherited neurological condition, with a reported
prevalence 1/2500 [1]; a prevalence 1/1214 has also been
noted [2]. IPN is an example of a genetically highly het-
erogeneous group of disorders. Mutations in more than
90 genes are already associated with IPN [3, 4].
Our Center for inherited neuropathies in Charles Uni-
versity in Prague and University Hospital Motol is
unique for the whole Czech Republic. In the course of
17 years, we have collected DNA samples and clinical* Correspondence: petra.lassuthova@gmail.com
1Department of Paediatric Neurology, DNA Laboratory, 2nd Faculty of
Medicine, Charles University in Prague and University Hospital Motol, Prague,
Czech Republic
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zedata from more than 3100 patients from 2155 independ-
ent families. The cause of inherited neuropathy has been
stated in 920 unrelated families (1775 patients), so far.
In the previously diagnosed 920 families, PMP22
duplication was detected in 412 families (772 patients),
PMP22 deletions were detected in 290 families (485
patients) and in the remaining 218 families (518 patients)
causative point mutations in known CMT genes were
detected.
However, molecular genetic diagnosis was still unknown
in approximately 1378 patients (from 984 unrelated
families). Sanger sequencing of individual genes is time
consuming and not very successful for many less frequent
causes of IPN. Targeted resequencing with a gene panel
was therefore a promising option in such situations. Itle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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which are associated with inherited neuropathies, in real
time, in massively parallel mode.
Methods
The study was approved by the ethics committee of
University Hospital Motol and informed consent was
obtained from all patients. A permission was obtained to
publish the personal information essential for the under-
standing of the manuscript.
Patients
One hundred and ninety-eight patients (affected unrelated
patients) from 198 unrelated families were included in
the study. These patients were selected according to the
following criteria:
1. IPN phenotype (peripheral neuropathy motor and/
or sensory) supported with nerve conduction
studies, with no other detectable acquired cause;
2. Availability of other family members for
molecular- genetic testing;
3. Patients were previously tested for CMT1A
duplications and HNPP deletions in relevant
cases. Moreover, most relevant or common
IPN genes have already been tested in all
patients with Sanger sequencing dependent
on the provided clinical and electrophysiological
and family data and these tests did not identify
causal mutation; this is shown in Additional file 1:
Part 1/figure A.Fig. 1 Age at onset of the disease (study cohort). For 77 % of probands inclu
available. These are represented in the graph Age at Onset. For 23 % of proba
age at referral for these probands is shown, as this may also be a useful surro
age group; age groups are described as intervals in years, and percentage of
study, 60 % of them had onset of the disease before the age of 20 yearsFrom the patients included in the study: fifty-nine
patients were reffered with demyelinating neuropathy
(HMSN I), ninety-three patients were reffered with axonal
neuropathy (HMSN II). Eight patients were classified as
having intermediate neuropathy. The remaining patients
were classified as having HMSN or IPN without more
details (Additional file 1: Part 1). The majority of selected
patients were sporadic cases (Additional file 1: Part 1).
Patients were referred to our department by neurolo-
gists, clinical geneticists and neuromuscular centres from
the whole Czech Republic over a period of 17 years
(1998–2015). The age of onset of the disease in probands
tested in this study is shown in Fig. 1. Sixty percent of
patients had the age of onset before the age of 20 years.
Targeted resequencing
HaloPlex technology (Agilent Technologies, Santa Clara,
USA) was used.
Design
NGS HaloPlex target enrichment library design was
created with SureDesign application provided by Agilent
(Agilent Technologies, Santa Clara, CA, USA). Genes
were included in the design based on these criteria:
1. At least two independent literature reports exist
(“known IPN genes”).
2. “New” genes were also included in the design, if the
primary report presented:ded in
nds th
gate (g
probana. evidence for pathogenic mutations in at least two
unrelated familiesthe study the data about the age at onset of the disease were
ese data were not readily available (N.A./ not available), however,
raph Age at referral). Each block in the graph represents a different
ds with onset/referral is shown. From probands included in the
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family; The family was larger than a nuclear
family and evidence was supported by functional
studies.
3. Also, five candidate IPN genes were included in
the design. The idea behind this was to search for
a second family with mutation in the same gene
and similar IPN phenotype, and thus to”confirm”
the gene.
Three genes were selected from a paper by Schabhuttl
et al. [5]: SH3PB4, ITPR3 and KLHL13 genes.
Moreover, SLC18A3 gene was also included in the de-
sign, based on our WES study in one Czech family. A pos-
sibly pathogenic de-novo mutation has been detected with
trio analysis in this gene by the de-novo approach. How-
ever, the phenotype in this family is very unique [6] and
we have not yet been able to find the second family.
Also, mutation in MICAL1 gene has been found in
one Czech family with combination of linkage and WES
analysis. However, further studies and analyses have
shown that the variant is probably only a VUS (variant
of unknown significance), and the relationship between
MICAL1 gene and IPN has not been proved. This gene
will therefore not be included in future designs.
Overall, five consecutive designs were prepared. A list
of genes is available in Additional file 1: Part 2.
Sequencing
Prepared libraries were pooled and sent out for sequen-
cing, performed in an outsorced laboratory – EMBL gen-
omics core facilities (Heidelberg, Germany). Instrument




SureCall default Firstly, all fastq files were analyzed in
SureCall application with default settings (Agilent_Sure-
Call_2.1.0.21). Afterwards, for every sample a vcf file was
generated with no filters applied. These vcf files were then
merged into one vcf file with Galaxy installation of the vcf
combine tool [7]. Merged vcf was then evaluated in several
steps. In the first step, this vcf file was loaded into Genome-
Trax tool (BioBase International, Qiagen Company, MA,
USA). This tool identified all known mutations, previously
reported in Human Gene Mutation Database (HGMD®
Professional, BioBase International, Qiagen Company, MA,
USA). Merged vcf was also annotated with Annovar [8].
SureCall coverage10 Secondly, files were analysed in
the SureCall application with more relaxed settings. This
analysis method has been called SureCall coverage10 forworking purposes. Differences from default settings are
mainly in SNP filter settings. The aim of this analysis was
to call variants that were covered sufficiently, but not called
– because the default settings in SureCall are set to call
variants covered at least 40x. Analysis SureCall coverage10
was set to call variants covered at least 10x. This has raised
the false positives, however, we decided to include this step
in analysis because:
1. This approach has led to finding the causal mutation
in five more patients. These mutations would have
been missed by default approach only.
2. This approach was used as a second step, and a
combination of default settings analysis in the first
step with relaxed analysis in the second step has
turned out to be most effective as this is
combination of high specificity (default settings) and
high sensitivity (relaxed settings) analysis process.
Vcf files were generated in the same manner, and analysed
similarly as reported above.
Galaxy analysis
For high sensitivity of the analysis, we also decided to
include in the workflow an analysis with our own pipe-
line based in Galaxy[7]. The schematic representation of
the pipeline and Galaxy pipeline parameters and pipeline
resources are listed in Additional file 1: Part 3.
In-house database of variants in MySQL
All three analyses were processed for all samples. For our
own purposes and for comprehensibility we developed
our own in-house database of variants in the MySQL
environment.
Variants evaluation
All called variants were subjected to a review.
Variants were classified as:
1) rare benign variants if having EVS frequency more
than 4 % or were present in more than 3 samples
out of 48 or more (one run) or cumulative
frequency was more than 5 alleles out of 198
patients.
2) remaing variants were evaluated with Alamut
software (Interactive Biosoftware, http://
www.interactive-biosoftware.com/). Called variants
were classified according to recommendation by
American College of Medical Genetics and
Genomics (ACMG) [9].
Variants confirmation
Variants listed as DM and DM? in HGMD® Professional
OR classified as pathogenic or likely pathogenic (category
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Additional file 1: Part 4 were further analyzed and were
considered to be variants of interest.
Firstly, variants of interest were confirmed by Sanger
sequencing. During the process a relatively large number
of primers for PCR must be designed. We have used
Optimus primer [10]. Afterwards, if a variant has been
confirmed with Sanger sequencing, we proceeded to seg-
regation analysis of the variant with the disease in the
family. All other available family members were tested
for presence or absence of this variant.
Importantly, the phenotype of the patient was evaluated
in the scope of the tested variant.
Drawing a conclusion about a variant
Based on a recommendation from ACMG [9] the follow-
ing conclusions have been made:
1. “positive”: A detection of mutation that explains a
patient’s condition.FigFor variants previously reported as pathogenic,
confirmed by Sanger sequencing and also segregation
of the variant with the disease in the family, was
tested and proved. Moreover, the clinical phenotype
of the patient was critically evaluated against the
literature reports and our own clinical experience.
This conclusion was made also for novel variants in
known IPN genes, if the variant fullfiled criteria in
Additional file 1: Part 4 and again the variant was
confirmed by Sanger sequencing and also
segregation of the variant with the disease in the
family, and was tested and proved. Also, the
phenotype of the patient is consistent with what has
been described before in the literature and our own
clinical experience.. 2 Causal variants in these genes have been found. Legend: X – axis: g2. “negative” (no variants identified of likely relevance
to the diagnostic indication)
For this conclusion to be made, we required the
NGS data to pass quality criterion: at least 97 % of
targeted bases is covered at least 10x. Otherwise,
the library for the sample would have been
prepared again.
3. “inconclusive” (a clear explanation of the patient’s
condition was not found either due to only variants
of unknown significance being identified or due to
only a single heterozygous variant identified for a
recessive condition)”
CNV analysis
Data for the remaining one hundred and forty-seven
patients were further tested with other algorithms with
the aim of finding the causal mutations. Copy number
variation analysis was performed with three different ap-
proaches – firstly, SureCall analysis (Agilent Technologies,
CA, USA) predicts CNVs based on log ratio of the nor-
malized sample read depth to the reference sample read
depth. Secondly, NextGene (SoftGenetics LLC., PA, USA)
analysis based on hidden Markov model (HMM) and
lastly, NextGene analysis based on data normalization (in
beta testing version) were performed.
Results
Causal variants
Causative mutations have been found in 51 independent
patients (Fig. 2) and in 21 genes. Pathogenic mutations
detected in the study and genotypes of the patients in
whom the genetic diagnosis was established are presented
in Table 1.
From 51 clarified patients with causal pathogenic muta-
tions the age of onset of the disease was in the first orenes; Y – axis: number of patients with causal mutation
Table 1 Genotypes of patients with pathogenic mutations
Gene Ref. sequence No. of unrelated families
with the mutation
Variations at DNA-level (relative
to coding DNA sequence)
Variation at protein
level (deduced)
AARS (NM_001605.2) 3 c.986G>A p.Arg329His
ATP7A (NM_000052.6) 1 c.2981C>T p.Thr994Ile
BSCL2 (NM_032667.6) 2 c.263 A>G p.Asn88Ser
BSCL2 (NM_032667.6) 1 c.269 C>T p.Leu90Ser
COX6A1 (NM_004373.2) 1 c.[247-7_247-3del];[c.247-7_247-3del]
DYNC1H1 (NM_001376.4) 2 c.1792 C>T p.Arg598Cys
EGR2 (NM_000399.3) 1 c.1231G>A p.Asp411Asn
FBLN5 (NM_006329.3) 1 c.1117C>T p.Arg373Cys
FIG4 (NM_014845.5) 1 c.[498-1G>A];[122T>C]
FIG4 (NM_014845.5) 2 c.[793C>T];[122T>C] p.[Arg265*];[Ile41Thr]
GDAP1 (NM_018972.2) 1 c.715C>T p.Leu239Phe
GJB1 (NM_000166.5) 1 c.88A>T p.Ile30Phe
GJB1 (NM_000166.5) 1 c.641dup p.Arg215Profs*28
GJB1 (NM_000166.5) 1 c.622G>A p.Glu208Lys
GJB1 (NM_000166.5) 1 c.212T>C p.Ile71Thr
GJB1 (NM_000166.5) 1 no amplification (deletion),
confirmed with MLPA
HINT1 (NM_005340.5) 2 c.[110G>C];[110G>C] p.[Arg37Pro];[Arg37Pro]
HSPB1(HSP27) (NM_001540.3) 1 c.505_506dup p.Met169Ilefs*5
HSPB3 (NM_006308.2) 1 c.21G>T p.Arg7Ser
INF2 (NM_022489.3) 1 c.383T>C p.Leu128Pro
INF2 (NM_022489.3) 1 c.233T>C p.Leu78Pro
INF2 (NM_022489.3) 1 c.162-173del p.Lys55_Glu58del
LITAF (NM_001136472.1) 1 c.334G>A p.Gly112Ser
MFN2 (NM_014874.3) 1 c.280 C>T p.Arg94Trp
MFN2 (NM_014874.3) 1 c.436 C>T p.Leu146Phe
MFN2 (NM_014874.3) 1 c.493 C>T p.His165Tyr
MFN2 (NM_014874.3) 1 c.701T>A p.Met234Lys
MFN2 (NM_014874.3) 1 c.839G>A p.Arg280His
MFN2 (NM_014874.3) 1 c.880C>T p.Arg294*
MFN2 (NM_014874.3) 1 c.1081C>T p.His361Tyr
MFN2 (NM_014874.3) 1 c.1090 C>T p.Arg364Trp
MFN2 (NM_014874.3) 1 c.1574A>G p.Asn525Ser
NDRG1 (NM_001135242.1) 1 c.442 C>T p.Arg148*
NEFL (NM_006158.4) 1 c.310T>G p.Phe104Val
NEFL (NM_006158.4) 1 c.1186G>A p.Glu396Lys
PMP22 (NM_153322.1) 1 c.124T>C p.Cys42Arg
PMP22 (NM_153322.1) 1 c.421_436del p.Val141Profs*9
SETX (NM_015046.5) 1 c.[1656G>T(;)1658C>T] p.[(Gln552His(;)Ser553Phe)]
SBF2 (NM_030962.3) 1 c.[134T>A];[c.134T>A] p..[Ile45Asn];[Ile45Asn]
SEPT9 (NM_001113491.1) 1 heterozygous large duplication,
confirmed with MLPA
SH3TC2 (NM_024577.3) 1 c.[2860C>T];[c.279G>A] p.[Arg954*];[Lys93Lys]
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Table 1 Genotypes of patients with pathogenic mutations (Continued)
SH3TC2 (NM_024577.3) 1 c.[2860C>T];[1447T>G] p.[Arg954*];[Phe483Val]
SH3TC2 (NM_024577.3) 1 c.[2860C>T];[c.2812C>T] p.[Arg954*];[His938Tyr]
SPTLC2 (NM_004863.3) 1 c.1144G>C p.Gly382Arg
TRPV4 (NM_021625.4) 1 c.557G>A p.Arg186Gln
Total 51
Legend (based on HGVS recommendations)
Two changes in one gene on different chromosomes (e.g., in recessive diseases) are shown as for example p.[Arg37Pro];[Arg37Pro]; this describes two changes in
trans (derived from a gene on each chromosome (one paternal, one maternal)
*Termination codon
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30 years was associated with only a very low chance for
clarification. This is represented in Fig. 3.
Some of the variants are described in detail below. We
decided not to include detailed description for patho-
genic variants which are common and clinical phenotype
is presented in great detail elsewhere [11–16].
AARS (NM_001605.2): c.986G>A
Mutation p.Arg329His (c.986G>A) was found in three
families with IPN. This mutation has been previouslyFig. 3 Age of onset of the disease (patients with pathogenic mutations).
Legend: The graph represents the age of onset of the disease for 51
patients with causal pathogenic mutations found in the study. Each
block in the graph represents a different age of onset group; age groups
are described as intervals in years, and percentage of probands with
onset is shown. Almost 70 % of causal mutations were found in patients
with early onset (before the age of 20), only 30 % of mutations were
found in patients with onset of the disease in the third life decade
or laterdescribed in a large French family [11]. Segregation of
the mutation has been tested. Pedigrees are shown in
Additional file 1: Part 5.
Clinically, the family 826 presented with axonal neur-
opathy with autosomal dominant inheritance. The index
patient’s (V/4) examination is presented in Additional
file 1: Part 5.
The patient was re-examined recently (at the age of 41).
Very slow progression of the disease was observed.
DYNC1H1 (NM_001376.4): c.1792 C>T
A mutation p.Arg598Cys (c.1792 C>T) in DYNC1H1 gene
was found in two originally independent patients with
early infantile onset of HMN or dSMA which later turned
out to be closely related but having different surnames.
The phenotype of the patient is compatible with SMALED
(SMA with lower limb predominance) since the weakness
on lower limbs is severe, but the upper limbs are almost
unaffected and even the EMG examination was normal
on upper limbs in some of the patients. The mutation was
rated as causal with high probability. In the meantime, the
mutation was also described in a young patient with simi-
lar phenotype [17].
GJB1 deletion
A large deletion of the GJB1 gene was found by our CNV
analysis in one patient with progressive peripheral motor
and sensory neuropathy. The deletion of the entire GJB1
was later also confirmed by Multiplex Ligation-dependent
Probe Amplification (MLPA, MRC-Holland, NL). The
SALSA MLPA P129-B1 GJB1 probemix was used. The
patient presented with classical CMTX1 phenotype, but
what was atypical for CMTX1 is the sporadic occurrence
in the family due to a de-novo mutation.
NDRG1 (NM_001135242.1): c.442 C>T
A homozygous mutation p.Arg148* in the NDRG1 gene
was surprisingly detected in a five years old patient with no
obvious Roma origin. The mutation in heterozygous state
was also detected in the father, but surprisingly not in the
mother. A complete isodisomy of chromosome eight of pa-
ternal origin was confirmed with other methods. The pro-
band is a homozygote for the mutation due to a paternal
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(CMT4D) has been stated [18].
Even more surprising was that the patient is also a het-
erozygous carrier of the mutation p.Arg113* in the REEP1
gene (NM_022912.2). This mutation has been already
described as pathogenic for hereditary spastic paraple-
gia [19]. However, a segregation analysis showed that a
healthy father and a healthy grandfather of the proband
are also heterozygous carriers of this variant. Both of them
deny having any sort of neurological problems and were
also neurologically examined with normal gait, normal re-
flexes and no weakness. It has been therefore concluded
that this variant is not causal in this particular family and
may be a harmless variant.
SETX (NM_015046.5): c.[1656G>T(;)1658C>T]
A patient with progressive distal, but also proximal muscle
weakness was reffered to our department when he was
11 years old. No other family members are affected. Muscle
weakness, mainly on lower limbs, was noticeable from
preschool age and is progressive. At examination at the
age of 13 he presented with pronounced proximal and
distal muscle weakness, muscle atrophies but also brisk
reflexes, what is sometimes seen in HMN patients. He has
problems with running and climbing. He is not able to
squat. Electrophysiology revealed axonal polyneuropathy
predominantly on motor nerve fibres compatible with
HMN or dSMA.
The mutation c.[1656G>T(;)1658C>T] in SETX gene
was detected. It was not detected in patient’s parents. We
concluded the mutation arose de-novo and causes change
NM_015046.5>c.1656_1658delCTGinsTTT on one allele
of the SETX gene. The indel mutation causes the loss of 2
residues and the insertion of HisPhe (p.Gln552_Ser553de-
linsHisPhe). This is an in-frame mutation, however due to
the change of two aminoacids we concluded the mutation
is causal for ADSMA in this patient. De-novo origin and
patient’s phenotype further support this hypothesis. No
variants have been reported at this position of the SETX
gene in various databases (EVS, dbSNPbuild137, ESP,
dbSNP ShortVariants/Swiss Prot Variants).
Possibly pathogenic variants (further studies needed)
These are novel variants in known IPN genes (Table 2).
Reasons that support or oppose their pathogenic character
are presented in the Additional file 1: Part 6.
Likely benign variants
That are either listed in HGMD or are otherwise interest-
ing, but turned out to be rare benign variants are pre-
sented in Additional file 1: Part 7.
An extensive list of likely benign variants from our data-
base is presented in Additional file 1: Part 8. These variants
from our database were present in more than five samplesand are not present in Human Gene Mutation Database
(HGMD® Professional, BioBase International, Qiagen Com-
pany, MA, USA) and thus are considered to be rare benign
variants in our population (= variants present in more than
5 alleles in 198 patients = 6/396 = population frequency
1,51 % or more).
Discussion
Gene panel MPS enables testing of all yet known IPN gen-
etic causes, even very rare ones, at once in parallel, with
high coverage and low price per gene. Therefore gene
panel testing is truly the method of choice [20, 21] for un-
clarified patients.
A recent study by INC – Inherited neuropathy consor-
tium [22] has shown interesting data. In summary, we have
observed a similar pattern in the distribution of genetic
causes of IPN. The common CMT subtypes (PMP22dup/
del, GJB1, MFN2, MPZ) account for the vast majority of
clarified causes, 89.2 % of causes in INC group, 90,5 % of
causes in our cohort. This result shows that testing of
clinically selected patients for the relevant four most com-
mon causes is able to identify the molecular genetic cause
of inherited neuropathy in approximately 90 % of patients
in whom we are able to identify the cause with current
knowledge and methodology. This result also shows us that
the rarer types are, in reality, very or extremely rare, and in
summary, that mutations in all other known IPN genes
represent only approximately 10 % of yet known causes.
Our study is unique in several aspects such as the num-
ber of patients tested (one hundred and ninety-eight pa-
tients) and also in the methods used (targeted gene panel
resequencing with HaloPlex custom design kits provided
by Agilent was used). There are only a few similar reports
published to date regarding the results from gene panel
testing. Moreover, the utility of redesigning the panel
regularly according to current knowledge has also been
shown. Our results demonstrate that mutations in genes
only recently described and newly included into the panel
are responsible for more than 10 % of causes of inherited
neuropathies which were aetiologically clarified in this
study. Moreover, in our study we have shown, that gene
panel testing is a useful tool for rare and unexpected
causes of IPN, where the gene by gene approach would
only hardly detect the causal mutation. Old methods
(MLPA and Sanger sequencing of individual genes) were
able to identify causal variants in more than 97 % of all
patients (920 - before panel) and accordingly, gene panel
testing enabled us to identify further 3 % of causal muta-
tions (51- with the panel). However, this is a very impor-
tant contribution of the panel. We expect that most of
these 51 clarified patients would not have been clarified
without the gene panel. The causes are extremely rare or
unexpected due to various reasons and by single gene
testing the chance for clarification would be very low. On
Table 2 Novel variants in known IPN genes that are considered to be possibly pathogenic variants
Gene Ref. sequence Variations at DNA-level
(relative to coding DNA sequence)
Variation at protein
level (deduced)
Pathogenicity predictions Locus conservation ExAC (0.3.1)
allele frequency





T = 0.0017 %





A = 0.019 %





A = 0.0029 %





T = 0.0016 %





T = 0.0017 %





A = 0.0033 %




















C = 0.00084 %
SPTLC2 (NM_004863.3) c.1313del p.Cys438Leu fs*5 frameshift No
Legend: Data were analyzed using software: Alamut Visual version 2.8 (Interactive Biosoftware, Rouen, France)[2016-07-21]
SIFT- D deleterious, T tolerated
MT Mutation Taster, DC disease causing
PP2 PolyPhen2, B benign
Conservation: N nucleotide, AA amino acid; M moderate, W weakly
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gene panel is clearly not rational as the first or even second
test.
Through targeted gene panel sequencing many interes-
ting findings were revealed:
Patient with HMSN-Lom with a homozygous mutation
in the NDRG1
Findings such as complete isodisomy of the whole
chromosome could not be expected. This case
illustrates the posibillities of targeted gene panel
sequencing. The proband would not have been
tested for this specific Roma mutation with
Sanger sequencing, because it would not have
been suspected and the diagnosis could have
been missed.
Patient with GJB1 gene deletion
This patient was planned for testing with Sanger
sequencing of the GJB1 gene. With routinely used
PCR primers for amplification of exon 2 of the GJB1
gene a PCR product of similar length than would be
expected was obtained, but it was not possible to
sequence this product. Afterwards, targeted gene
panel resequencing with HaloPlex was performed.
From generated bam. files, almost zero coverage
was observed for the GJB1 gene region.The deletion of the entire GJB1 was later confirmed also
by MLPA (Salsa P-0129, MRC-Holland, Amsterdam, the
Netherlands). We also send the patient’s DNA sample for
SNP microarray testing. The results confirmed the
deletion of the Xq13.1 region including the region of the
GJB1 gene in the patient, but not in his mother. Large
deletions of the region have already been described [23].
This example illustrates the ability of gene panel mas-
sively parallel sequencing to detect also larger copy number
variations, especially in the hemizygous or homozygous
state.
Ragarding the mutation in SETX
(NM_015046.5):p.[(Gln552His(;)Ser553Phe)],
c.[1656G>T(;)1658C>T]
We consider this mutation to be causal in our patient.
It is interesting to highlight some features of the clin-
ical phenotype, especially brisk reflexes. Other patients
described in the literature presented wih similar symptoms.
Our patients is only 15 years old. At this age, brisk reflexes
are described in HMN patients. Later in the course of the
disease, reduced/absent reflexes are described. Brisk reflexes
might be a transient phenomenon in the timeline of this
disease.
There is a discussion about classification of this pheno-
type. It might be true that ALS4 and ADSMA are terms
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however, some authors prefer to distinguish these two
entities. We think that our patient fits best the phenotype
described by Sabine Rudnik-Schoneborn as ADSMA [24].
Old mistakes
Targeted gene panel resequencing also revealed some old
“mistakes”. A representative example is a patient with
mutation p.Glu208Lys in the GJB1 gene. This patient was
previously tested for GJB1 mutations in the year 2002, but
no mutation was found at that time. Unfortunately, this
was caused by a sample or PCR product exchange by a
laboratory technician. Gene panel testing is thus also a use-
ful cross-check for all previous Sanger sequencing tests.
Mutations in common IPN genes
The high proportion of patients with mutations in com-
mon IPN genes (PMP22 – 2 patients, GJB1 – 5 patients,
MFN2 – 9 patients) detected in this study might also be
surprising. These genes are widely routinely tested in our
lab in relevant patients. However, these patients were not
tested for mutations in these genes mainly because the
clinical information we obtained was misleading or incom-
plete. For some of those patients the type of neuropathy
was misclassified (demyelinating vs. axonal), for some
patients the type of inheritace in the family (autosomal
dominant vs. autosomal recessive) was misclassified. To
conclude, targeted gene panel resequencing is not only able
to identify mutations in rare genes, but is also a powerful
tool for searching for mutations in common IPN genes. It
certainly might happen that some of the patients enter
genetic testing with improper or insufficient clinical data.
These patients are then tested for mutations in different
genes than would be appropriate. Not only are such tests
useless but also the diagnostic process is hindered for a
long time. This experience further supports the urgent
need for as much clinical data as possible on one side and
the need for effective genetic testing with careful clinical
evaluation before testing on the other.
The utility of redesigning the panel every six months
In our approach, we have developed our own custom
designed gene panel. There were five respective designs,
updated approximately every six months. The first gene
panel design consisted of 59 genes, the second of 64, the
third of 69, the fourth of 78 genes and the fifth of 93
genes.
From new genes that were just added, mutations were
found in a significant proportions of them, pathogenic
mutations were found in genes ATP7A, COX6A1 and
DYNC1H1. Possibly pathogenic variants were found in
four other genes: BICD2, GNB4, ITPR3 and PDK3. These
results show that mutations in genes only recently de-
scribed in IPN, may be responsible for more than 10 % ofcauses of inherited neuropathies which were etiologically
clarified in this study.
It may be useful to retest unclarified patients on subse-
quent panels. However, during this study, this has not
been done, yet. Patients in this study were tested only
once with one panel design. Performing new testing for
negative patients may bring out new information. Retes-
ting by a panel is used only in selected patients and we
recommend it is considered against the possibility of
whole exome sequencing (WES) depending on the indi-
vidual situation.
Conclusions
In our study we have shown that targeted gene panel MPS
is a powerful tool in DNA testing of IPN. In a carefully
preselected cohort of patients we were able to identify the
cause of IPN in 26 % of patients. A substantial part of the
patients may have been detected by classical methods,
single gene Sanger sequencing, if all necessary information
about the patients and all previous processes have been
correct.
In one-sixth of the patients (16 %) the results were
inconclusive, mostly because a likely pathogenic variant in
known IPN gene was found. In most of the tested genes,
causal mutations were found in only a single patient or
family, and only in twelve genes out of 93 were causal
mutations found in two or more independent patients.
Gene panel enables testing of all yet known IPN causes
in parallel with high coverage and at an affordable cost. It
is therefore truly the method of choice for patients unclar-
ified by previous testing of the most common and relevant
causes of IPN.
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